<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04154332</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-300004235</org_study_id>
    <nct_id>NCT04154332</nct_id>
  </id_info>
  <brief_title>Exosome Cargo From Preeclampsia Patients</brief_title>
  <official_title>Exosome Cargo From Preeclamptic Patients Mediates Endothelial Dysfunction, Subsequent Cardiovascular Remodeling, and the Preeclamptic Phenotype</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Although extensively studied, the cause of preeclampsia remains uncertain other than it is&#xD;
      thought that the placenta plays a critical role in the development of preeclampsia. Recent&#xD;
      data revealed that exosomes released from the placenta could cause preeclampsia by&#xD;
      transporting specific cargo responsible for the pathophysiological changes associated with&#xD;
      the systemic disease. By isolating these exosomes from maternal blood and placental tissue in&#xD;
      patients diagnosed with preeclampsia and studying their biochemical, cellular and molecular&#xD;
      mechanism in an animal model, the investigators hope to elucidate the critical role that&#xD;
      exosomal cargo plays in the development of preeclampsia and cardiovascular remodeling. This&#xD;
      will be accomplished by obtaining patient samples from volunteers delivering at the Women and&#xD;
      Infants Center and taking the samples to the lab for quantification, characterization, and&#xD;
      identification of key functional roles through in/ex vivo, in vitro, and profiling studies.&#xD;
      The investigators believe this work will be valuable as hope exists to define the functional&#xD;
      role exosomes play in the development of preeclampsia that leads to cardiovascular&#xD;
      remodeling. Data from this study will shed more light on the functional role of exosomal&#xD;
      cargo in normal and pathological pregnancies and point towards novel therapeutic intervention&#xD;
      strategies for preeclampsia associated with cardiovascular disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2, 2019</start_date>
  <completion_date type="Anticipated">November 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 15, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Exosome cargo levels</measure>
    <time_frame>Through study completion, average of four hours of involvement time total, after informed consent discussion</time_frame>
    <description>Researchers and investigators will attempt to quantify the amount of exosome abnormalities that may be present among patient populations who exhibit the preeclampsia phenotype.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Preeclampsia</condition>
  <arm_group>
    <arm_group_label>Healthy Controls</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Preeclampsia Group</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sample collection</intervention_name>
    <description>Blood, urine, and placental samples will be collected from each person enrolled in this study.</description>
    <arm_group_label>Healthy Controls</arm_group_label>
    <arm_group_label>Preeclampsia Group</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood, urine, and placental tissue samples will be collected from each subject enrolled.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Representative of the local population delivering at the university women and infant&#xD;
        center.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion&#xD;
&#xD;
          1. Preeclampsia patients: Age ≥ 18 years; Diagnosis of preeclampsia with severe features:&#xD;
             (a) BP ≥160/110 after 20 weeks gestation AND ≥300 mg/day proteinuria or&#xD;
             protein/creatinine ratio of 0.3 mg/dL; OR (b) BP ≥160/110 after 20 weeks gestation&#xD;
             with any of the following co-conditions: platelet count less than 100,000 X 109/L,&#xD;
             AST/ALT enzymes elevated to twice the upper limit of normal, serum creatinine ≥1.1&#xD;
             mg/dL or a doubling of the creatinine from baseline, pulmonary edema, new-onset&#xD;
             headache, and/or visual disturbances.&#xD;
&#xD;
          2. Control patients: Age ≥ 18 years; no diagnosis of preeclampsia or any&#xD;
             pregnancy-induced hypertension disorder.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Preeclampsia patients: Age &lt; 18 years; Any other diagnosis of pregnancy-induced&#xD;
             hypertension that isn't preeclampsia with severe features (i.e. gestational&#xD;
             hypertension or preeclampsia without severe features).&#xD;
&#xD;
          2. Control Patients: Age &lt; 18 years; Any diagnosis of pregnancy-induced hypertension.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark F Powell, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kera N Marshall, BS</last_name>
    <phone>205-934-4042</phone>
    <email>Keramarshall@uabmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ayesha Bryant, MD, MSPH</last_name>
    <phone>205-934-4696</phone>
    <email>Asbryant@uabmc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kera N Marshall, BS</last_name>
      <phone>205-934-4042</phone>
      <email>Keramarshall@uabmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Ayesha Bryant, MD, MSPH</last_name>
      <phone>205-934-4696</phone>
      <email>asbryant@uab.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Mark F Powell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 1, 2019</study_first_submitted>
  <study_first_submitted_qc>November 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2019</study_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Mark Powell</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pre-Eclampsia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

